These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 3111687)

  • 1. High-dose i.v. thiotepa and cryopreserved autologous bone marrow transplantation for therapy of refractory cancer.
    Lazarus HM; Reed MD; Spitzer TR; Rabaa MS; Blumer JL
    Cancer Treat Rep; 1987; 71(7-8):689-95. PubMed ID: 3111687
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I study of high-dose busulfan, melphalan and thiotepa with autologous stem cell support in patients with refractory malignancies.
    Weaver CH; Bensinger WI; Appelbaum FR; Lilleby K; Sandmaier B; Brunvand M; Rowley S; Petersdorf S; Rivkin S; Gooley T
    Bone Marrow Transplant; 1994 Nov; 14(5):813-9. PubMed ID: 7889015
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase I dose escalation study of high-dose thiotepa, melphalan and carboplatin (TMCb) followed by autologous peripheral blood stem cell transplantation (PBSCT) in patients with solid tumors and hematologic malignancies.
    Demirer T; Ilhan O; Mandel NM; Arat M; Günel N; Celebi H; Ustün C; Akan H; Demirer S; Aydintuğ S; Uysal A; Koç H
    Bone Marrow Transplant; 2000 Apr; 25(7):697-703. PubMed ID: 10745253
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-dose busulfan and thiotepa with autologous bone marrow transplantation in childhood malignant brain tumors: a phase II study.
    Kalifa C; Hartmann O; Demeocq F; Vassal G; Couanet D; Terrier-Lacombe MJ; Valteau D; Brugieres L; Lemerle J
    Bone Marrow Transplant; 1992 Apr; 9(4):227-33. PubMed ID: 1534708
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intensive melphalan chemotherapy and cryopreserved autologous bone marrow transplantation for the treatment of refractory cancer.
    Lazarus HM; Herzig RH; Graham-Pole J; Wolff SN; Phillips GL; Strandjord S; Hurd D; Forman W; Gordon EM; Coccia P
    J Clin Oncol; 1983 Jun; 1(6):359-67. PubMed ID: 6366139
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I trial of high-dose melphalan, high-dose etoposide and autologous bone marrow re-infusion in solid tumors: an Eastern Cooperative Oncology Group (ECOG) study.
    Lazarus HM; Gray R; Ciobanu N; Winter J; Weiner RS
    Bone Marrow Transplant; 1994 Sep; 14(3):443-8. PubMed ID: 7994270
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Phase I dose escalation trial of continuous infusion paclitaxel to augment high dose cyclophosphamide and thiotepa plus stem cell rescue for the treatment of patients with advanced breast carcinoma.
    Zimmerman TM; Grinblatt DL; Malloy R; Williams SF
    Cancer; 1998 Oct; 83(8):1540-5. PubMed ID: 9781947
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A study of thiotepa, etoposide and fractionated total body irradiation as a preparative regimen prior to bone marrow transplantation for poor prognosis patients with neuroblastoma.
    Kamani N; August CS; Bunin N; Leahey A; Bayever E; Goldwein J; Zusman J; Evans AE; Angio GD
    Bone Marrow Transplant; 1996 Jun; 17(6):911-6. PubMed ID: 8807093
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The additive effect of peripheral blood stem cells, harvested with low-dose cyclophosphamide, to autologous bone marrow reinfusion on hematopoietic reconstitution after ablative chemotherapy in breast cancer patients with localized disease.
    de Graaf H; Mulder NH; Willemse PH; van der Graaf WT; Sleijfer DT; Zijlstra JG; Elias M; Sibinga CT; Vellenga E; de Vries EG
    Anticancer Res; 1995; 15(6B):2851-6. PubMed ID: 8669878
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High-dose thiotepa with autologous bone marrow rescue in pediatric solid tumors.
    Saarinen UM; Hovi L; Mäkipernaa A; Riikonen P
    Bone Marrow Transplant; 1991 Nov; 8(5):369-76. PubMed ID: 1768972
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High-dose N,N',N"-triethylenethiophosphoramide (thiotepa) with autologous bone marrow transplantation: phase I studies.
    Wolff SN; Herzig RH; Fay JW; LeMaistre CF; Brown RA; Frei-Lahr D; Stranjord S; Giannone L; Coccia P; Weick JL
    Semin Oncol; 1990 Feb; 17(1 Suppl 3):2-6. PubMed ID: 2106165
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A feasibility study of multiple cycle therapy with melphalan, thiotepa, and paclitaxel followed by mitoxantrone, thiotepa, and paclitaxel with autologous hematopoietic cell support for metastatic breast cancer.
    Hu WW; Long GD; Stockerl-Goldstein KE; Johnston LJ; Chao NJ; Negrin RS; Blume KG
    Clin Cancer Res; 1999 Nov; 5(11):3411-8. PubMed ID: 10589752
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-dose combination alkylating agent preparative regimen with autologous bone marrow support: the Dana-Farber Cancer Institute/Beth Israel Hospital experience.
    Antman K; Eder JP; Elias A; Shea T; Peters WP; Andersen J; Schryber S; Henner WD; Finberg R; Wilmore D
    Cancer Treat Rep; 1987 Feb; 71(2):119-25. PubMed ID: 3542208
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High-dose cyclophosphamide, thiotepa, and carboplatin with autologous marrow support in women with measurable advanced breast cancer responding to standard-dose therapy: analysis by age.
    Antman K; Ayash L; Elias A; Wheeler C; Schwartz G; Mazanet R; Tepler I; Schnipper LE; Frei E
    J Natl Cancer Inst Monogr; 1994; (16):91-4. PubMed ID: 7528031
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II study of high-dose thiotepa and hematopoietic stem cell transplantation in children with solid tumors.
    Lucidarme N; Valteau-Couanet D; Oberlin O; Couanet D; Kalifa C; Beaujean F; Lapierre V; Hartmann O
    Bone Marrow Transplant; 1998 Sep; 22(6):535-40. PubMed ID: 9758339
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of metastatic malignant melanoma with intensive melphalan and autologous bone marrow transplantation.
    Lazarus HM; Herzig RH; Wolff SN; Phillips GL; Spitzer TR; Fay JW; Herzig GP
    Cancer Treat Rep; 1985 May; 69(5):473-7. PubMed ID: 3891085
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High-dose sequential chemotherapy and autologous stem cell reinfusion in advanced pediatric solid tumors.
    Chan KW; Petropoulos D; Choroszy M; Herzog C; Jaffe N; Ater J; Korbling M
    Bone Marrow Transplant; 1997 Dec; 20(12):1039-43. PubMed ID: 9466276
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dose escalation of mitoxantrone given with thiotepa and autologous bone marrow transplantation for metastatic breast cancer.
    Bowers C; Adkins D; Dunphy F; Harrison B; LeMaistre CF; Spitzer G
    Bone Marrow Transplant; 1993 Nov; 12(5):525-30. PubMed ID: 8298564
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activity of interleukin-2 in non-Hodgkin's lymphoma following transplantation of interleukin-2-activated autologous bone marrow or stem cells.
    van Besien K; Margolin K; Champlin R; Forman S
    Cancer J Sci Am; 1997 Dec; 3 Suppl 1():S54-8. PubMed ID: 9457395
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of continuous-infusion high-dose thiotepa.
    Henner WD; Shea TC; Furlong EA; Flaherty MD; Eder JP; Elias A; Begg C; Antman K
    Cancer Treat Rep; 1987 Nov; 71(11):1043-7. PubMed ID: 3119200
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.